Index

A & M Records Inc. v Napster Inc. 211, 215–16
AAMC 235
abuse of the patent system 47
academic freedom 221–2
accounting language 268–9, 270, 270–5
Adeney, E. 178
Administrative Judges 18
agreed patent database 20–2
agricultural biotechnology 63, 131–2
Alcazar, J.E. 145
Alkermes 66
all-species encyclopedia see Encyclopedia of Life
American Association for the Advancement of Science 231
American Physical Society 179
Anderson, C. 176–7
Angiotech Pharm. Inc. v Conor MedSystems Inc. 22–3
Anglo-Australian Copyright Acts 203, 213
antibiotics 14, 82
anticommons problem 69–71, 130, 131–2, 138–9
anti-poaching covenants 272–4, 277
arbitration, technical 4, 17–18
Arora, A. 66–7, 68, 70–1
Arup, C. 290, 300
arXiv 180
Ashby, E. 221
assets, knowledge 155–7
Association of American Publishers 183
Association of American Universities (AAU) 235
Association of University Technology Managers (AUTM) 225, 233, 234
Australia 1, 63, 101–25, 267, 289
Back ing Australia’s Ability (BAA) 237
biotechnology industry 74–5
clusters 287
commercialization of university research 221–49
objectives and policies 240–2
reviews and reform recommendations 237–40
Competition Principles Agreement (CPA) 103, 104–11, 122
Copyright Act 1968 108, 110, 122
default rules for patents and copyright 297
failure of small biomedical companies 67–8
human capital 301
induced patents 34–6
National Principles of Intellectual Property (NP) 238
nineteenth century newspapers 200, 201
patent review 1984 29
Patents Act 1990 101–2, 102–3, 122
amendments and new practices 111
regulatory quality and performance according to the CPA 104–11
restrictive covenants 280–1, 282
split entitlements 298–9
Therapeutic Goods Act 1989 103
Trade Practices Act 1974 101, 102, 103–4, 111, 122, 267
justification for partial exemption of the Patents Act 103–4, 112–21
transaction costs 45
Australian Code for the Responsible Conduct of Research (the Code) 239
Australian Competition and Consumer Commission (ACCC) guidelines 118, 120
Australian National University (ANU) 250
Australian Universities Quality Audit (AUQA) 250
Australian Research Council (ARC) grant conditions 239
Authors’ Guild 183
authorship
collective 172–98
and ownership 177–80
Ayyangar Committee Report 82–3

background intellectual property 166–7

Backing Australia’s Ability – An Innovation Action Plan for the Future (BAA) 237
Bagchi, A.K. 87, 97
Baidu Baike 182–3
Bakels, R. 47
balance of probabilities evidence standard 111
Balkin, J. 194
ballads 199, 207, 212
Banerjee, P. 87, 97
Bar-Gill, O. 67
Barton, J. 46
Bartow, A. 32
Baser, S. 93
basic research 55
with immediately identifiable commercial application 222–3
Bayh–Dole Act 58–9, 225, 232, 233, 234, 243
bazaar governance 132, 146–7
Beesley, A. 177
Bell v Whitehead 203, 207
Benkler, Y. 5, 62, 133, 137, 177, 287, 294
Bently, L. 296
Berger, P. 156
Berlin University 221
Bernstein, L. 296
Berry, M. 287
Bessen, J. 11, 30, 32, 33, 38, 46
‘best endeavours’ clause 114–15
Bhattacharya, U.K. 87, 97
Bienstock, A. 233
bilateral agreements 16
BioBricks Foundation 142
biodiversity
Encyclopedia of Life see Encyclopedia of Life
open source community for crop biodiversity conservation 145
Biodiversity Heritage Library 189–90
BioForge 143
bioinformatics software, open source 145–6
Biological Innovation for Open Society (BIOS) 143–4, 161–2
Biological Open Source (BiOS) licensing 63, 143–4, 161–2
biomedical research 5, 55–79, 131
changing the biomedical business model 74–6
history 57–60
strong patent rights and the small firm 63–9
strong patent rights and the university 60–3
strong patent rights and weak patent standards 68–74
follow-on innovation 69–71
twenty-first century 71–4
bioscience 154–71
assets, property and capital in knowledge 155–7
intellectual property to promote innovation 154–5
open licence models 158–63
openness under certain conditions 165–8
possibilities for openness 158
biotechnology, open source see open source biotechnology
Bishop, E. 40
blocking 39
Board of Patent Appeals and Interferences 18
Bogsch, A. 15
Boland, M. 44
Botanicus 190
boundaries, patent 38, 46, 47
Bourdieu, P. 296
Boyce, G. 205
Boyer, H. 58, 61
Boyle, J. 130, 132, 142
Braithwaite, J. 4, 15
Brandt, D. 182
Brazil 80
BRCA2 159–61
breach of confidence cases 271
Index

Breen v Williams 271
British Technology Group 42
broadness of patents 72–3
Brooks, D. 191
Bureau of Industry Economics (BIE) 29–30
Burk, D. 57, 67
C. V. Starr Virtual Herbarium 190–1
Cactus Imaging Pty Ltd v Peters 268, 274
California 289, 293
judicial policy 298
CAMBIA (Center for Application of Molecular Biology in International Agriculture) 143–4, 161–2
Cancer Research Technology Ltd (CRTL) 159–61
capability market power 12–13
capital, knowledge 155–7
capital payments 25–6
capitalism 2, 286, 301–2
Carnegie-Mellon Survey (CMS) 32, 33, 39, 40
Carrigan, F. 295
cartels 82
Casper, S. 287
CC-BY (Attribution) 188
CC-BY-NC (Attribution-NonCommercial) 189
CC-BY-NC-SA (Attribution-NonCommercial-ShareAlike) 189
CC-BY-SA (Attribution-ShareAlike) 188
CCST 224
Ceccagnoli, M. 68
Chand Patents Enquiry Committee 82–3
chemicals industry 33, 86, 90–1, 97
Chicago School 293
China 80
Cho, C. 71
Citizendium 174, 182, 183–4
Clarke, R. 184
click-wrap database licence 141
clusters 285–305
complementary policies 300–2
furthering legal policy of split entitlements 293–300
policy 288–90
policy rationales and innovation 290–3
theory 285–8
coalition of poorer countries 16–17
Coase’s theorem 293
codified knowledge/information 60–1, 288
coercion of labour, freedom from 269–70, 270, 278–9
Cohen, N. 180
Cohen, S. 58
Cohen, W. 12, 39, 44, 68, 70–1
Cole, J. 38, 44
collaborations 189–91
collective action theory 26
collective authorship 172–98
Encyclopedia of Life 172, 174, 184–92
Collins, H. 270, 297
commercial offices 238
commercialisation
OSB and 134
university research 5, 221–49
areas of concern 226–7
benefits 228
defining commercialisation activity 224–5
international context 229–36
policy and development in Australia 237–42
practical problems in rejecting commercialisation 227–8
some degree of commercialisation as a sensible strategy 225–9
Commission of Intellectual Property Rights 131
common law doctrine making illegal restraints of trade 269, 270, 275–7, 281
common law obligations 297
commons-based peer production 132, 146–7
communities
interpretive communities 93–4
openness within 166–7
universities’ role in economic and social renewal 228
Community Patent Review project 20
competition
Australian competition law and patents 6, 101–25
competitors’ access to inventions 24–5
impacts of patent system 35, 42–5
innovation as competitive strategy 254–5
OSB and restructuring 137–8
patents regulating 256
problems with 255–6
Wikipedia’s imitators, competitors and rivals 182–4
Competition Principles Agreement (CPA) 103, 122
regulatory quality and performance of the Australian Patents Act 104–11
complementary proprietary products 137
complexity 91–2
compulsory licensing 24–5, 82–3, 111
Confederation of Indian Industry 85
confidence, equitable obligation of 260
confidential information 270–2, 276–7, 281, 298
confidentiality agreements 226
confidentiality clauses 260, 261, 262
conflicts of interest 226, 235
Congress Party 85
Conservapedia 182
conserved varieties register 145
Considine, M. 228
consumer surpluses 36–7
contextualisation 2, 306–7
contracts 307
contract law and restrictive covenants 6, 267–84
innovation by individuals and 257, 258–9, 259–62
psychological contracts 291
split entitlements 288–9, 293–7
contract practices 294–6
default rules 296–7
freedom of contract 293–4
control mechanisms, licences 160–1, 162
Controller of Patents and Designs 81
Cooper, D. 293
cooperative mechanisms 75
Copinger and Skone James on the Law of Copyright 203, 205
copyleft licences 134, 139, 147
copyright 3
default rules in Australia 297
and encyclopedias 175–6
online media 176, 178–82, 188–9, 192–4
and parallel importing 108–9, 110
and street literature 4, 199–217
marginal effect 200–1
new street literature 205–12
old street literature 199–205, 207
co-regulation 4
corporate capitalism 2, 286
costs and benefits of patent systems 29–54
corporation and resource allocation 35, 42–5
dissemination of information 35, 40–2
impacts on innovation 35, 36–40
induced patents 31–6
priorities 47–8
transaction/regulatory costs 36, 45–7
used patents 31–6, 43
Council on Governmental Relations (COGR) 236
Court of Appeals of the Federal Circuit (CAFC) 59
covenants 121
restrictive see restrictive covenants
Creative Cluster Study 289
Creative Commons 132
licences 188–9
creativity 250–1, 253–4, 307–8
optimal conditions for 257–9
Cukier, K. 141
Cunningham, S. 292
Cunningham, W. 172
Curran, J. 205
customer connection cases 272–3
DArT network 143
databases 89–90
agreed patent database 20–2
David, P. 168
Dean, R. 297
default rules 289, 296–7, 307
defensive patenting 32, 39, 68
deferred examination 90
Demil, B. 133
Department of Education, Science and Training (DEST) (Australia) 224
deregulation of labour markets 269–70
developing countries
coalition of 16–17
and patents 93–4, 96–7
*Diamond v Chakrabarty* 58
direct protection of innovation 22–6
disclosure 65–6
disparate innovation 251, 257
dispute settlement 17
patent litigation 17, 38, 45–6, 95–6
technical arbitration 4, 17–18
dissemination 5–6, 25–6
American universities and effectiveness of 235–6
Australian universities 239–40
impacts of patent system 35, 40–2
*Diversity Arrays Technology (DArT)* 142–3
doctrine against restraints 269, 270, 275–7, 281
*DNA patents* 72
Doha Round 94
Dormer, M. 37
double patenting 92
Drahos, P. 15, 93
Drews, J. 135
Dreyfuss, R. 5
*Drugs for Neglected Diseases Initiative* 142
dual licensing 148
dynamic efficiency 107

*Edison, T.* 39
*Edwards, C.* 33
*Edwards, J.* 187
*Eisenberg, R.* 56, 69–70, 130, 294, 295
Electronic Frontier Foundation 132
Eli Lilly 58
embryo-free human stem cells 250
employee entitlements to statutory IPRs 259
employment contracts see contracts
Encarta 176
encoded capacity building 94
*Encyclopedia Britannica* 176
Encyclopedia of Life 172, 174, 184–92
challenges 191–2
collaborations 189–91
legal dangers 188–9

*Endeshaw, A.* 39
*Ensembl Project* 185
entry of firms 44
environment 301, 309–10
Equitable Access licensing 144–5
equity 257, 259–62
Ergas Report 105–11, 116–19, 122
interim report 113–14
European Patent Observatory 47
European Patent Office (EPO) 41, 45, 93–4
Memorandum of Understanding with India 89–90
Research Fund 21
evergreening 92
examination of patents 73–4, 90
examiners, patent 3, 81–2, 89, 90, 93–4
excessive proprietary control 131, 138–9
exclusionary provisions 120, 121
exclusive marketing rights 85–6
exit of firms 44
exploitation incentives 291–2
expressed sequence tags (ESTs) 59

fair use
and free speech 203–4
new street literature 4, 208, 209–10, 211–12
rise of 202–3
wiki-based sites 180–2, 193
Fanton, J.F. 187
fast-track patent process 95
Ferry, G. 141
filing costs 45
financial conflicts of interest 226, 235
Firestone, O. 31
firms
entry and exit 44
incentives for innovation and the need for patents 251, 251–7, 262
large 286, 292
small see small firms
First, H. 5
‘flash of creative genius’ 14
Florida, R. 300, 301
follow-on innovation 69–71
*Folsom v Marsh* 206, 214–15
Food and Drug Administration (FDA) 21
foreign companies’ patent applications 87
foreign direct investment (FDI) 43
foreground intellectual property 166–7
François, D. 45
free/libre and open source software (FLOSS) 130, 132, 135, 147–8
programs for use in biotechnology
settings 145–6
free speech 203–4, 210–12
Free Republic case 206–12
implications for free speech 210–12
freedom of contract 293–4
freedom to operate 73

Gaughan, M. 286
Genentech 58, 61, 66
General Agreement on Tariffs and Trade (GATT) 15, 43, 84
General Public Licence for Plant Germplasm (GPLPG) 140
Geneva Declaration on the Future of the World Intellectual Property Organisation 194
Germany 13
Ghosh, R.A. 135, 178
Gilson, R. 293, 298
Glavá, M. 156
Gleevec 92–3
GNU Free Documentation License 178, 183
Godwin, M. 180
Goldilocks hypothesis 67
Gomory, R. 186
goodwill 268–9, 272, 273, 274–5
Google 177, 183, 184
Google Book Search 183
Gowers Report 20
grace period 111
Grayling, A.C. 204
Griliches, Z. 44
Group of Eight (Australian universities) 224
Growing Esteem 240
Grushcow, J. 42
Guaragna, M. 144
Guellec, D. 41
Hall, B. 65, 68–9
Hamied, Y.K. 82
Hanover Insurance Brokers Ltd v Schapiro 273
HapMap Project 76, 141
Hardy, I. 291–2
Harman, G. 227
harmonisation 22, 308, 310
Hartleys Ltd v Martin 273, 277–8
Heald, P. 43
Heller, M. 69–70, 130
Herbert Morris Ltd v Saxelby 269, 275
Heydon, J.D. 272
Higley, G. 188, 189
Hilmer Report 101, 122
hold-ups 39, 69–71
Hope, J. 4, 61, 63, 65, 133, 144, 146, 147, 148
Hopkins, M. 72, 73
Horn, L. 63
House of Representatives Standing Committee on Science and Innovation (HRSCSI) 225
Howard Report 224
Hugenholztz, P. 47
human capital policy 300–1
human genome project 59, 140–1, 185
human rights 269–70, 270, 278–9
humanitarian purposes 163
Humboldt, W. von 221
Hunt, R. 32
Hunter, D. 178, 205–6, 210, 211, 212
Hyde, A. 286, 291, 294, 298, 301
IBM 137
IceTV v Duncan Ross and Ors 278, 280, 282
immutable rules 289
Imperial College London 231
Imperial Innovations 231
improvements, right to 161–2
In the Public Interest: Nine Points to Consider in Licensing University Technology 233–4
inadvertent infringement 38
incentive rationale 268
incentives 250–66, 309
cluster policy and innovation 290–3
firms, innovation and the need for patents 251, 251–7, 262
individual innovation 251, 257–62, 262
to participate in OSB projects 134–8
pervasive 253–5
income from research, universities’ 227
incomplete contracts 295
incomplete production (wikis) 193
incontestability period 20–2
incremental innovation 24–5
independent invention 39
India 15
encouragement of R&D outsourcing to 90–1
Patents Act 1970 83–4, 86, 87, 88, 91–2, 95, 97
2005 amendment 92
Patents (Amendment) Act 2002 86
Indian Patent Office 3, 80–100
modernization 88–90
re-design of colonial institution 81–5
patent interpretive community 93–4
TRIPs 85–6, 94, 97
individuals
creativity 253, 257–9
incentives to innovate 251, 257–62, 262
legal mechanisms 259–62
optimal conditions for creativity 257–9
tension between systems and 309
induced patents 31–6
inducement doctrine 181
inherited values 221–2
injunctions 279–81
innovation 2–3, 307–8
clusters and 287, 290–3
direct protection of 22–6
disparate 251, 257
impacts of patent system 35, 36–40
incentives and 250–66
firms 251, 251–7, 262
individuals 251, 257–62, 262
intellectual property, innovation and openness 154–71
and patents in biomedical research 55–79
patents and investment in 11–12
Innovation Authority 23
innovation networks 229
innovation patents 23
innovation policies 230
innovation warrants 23
institutional conflicts of interest 226
insulin 58
intellectual property
assets, property and capital in
knowledge 155–6
background, foreground and sideground 166–7
and establishing openness 157–8
promotion of innovation 154–5
Intellectual Property Committee (IPC) 16
Intellectual Property and Competition Review Committee (IPCRC) 30
intellectual property policies, universities’ 238, 240–2
interference procedure 18
intermediaries 296
International HapMap Project 76, 141
international harmonisation 22, 308, 310
International Labour Organisation (ILO) Declaration of Fundamental Rights 269
International Patent Classification (IPC) system 95
International Searching Authority (ISA) status 80, 87, 89
international standardisation 7
International Treaty on Plant Genetic Resources for Food and Agriculture (ITPGRFA) 140
Internet 146–7
collective authorship 172–98
new street literature 205–12
Internet Corporation for Assigning Names and Numbers (ICANN) 184
interoperability 136, 192
interpreting communities 93–4
inventing around a patent 38–9
invention 22
inventive step requirement 72
inventiveness 253–4
investment in innovation 11–12
IPAC 40, 43
Italy 33
Jackson, J. 144
Jacobi Tool and Die v Mondi and Ors 280, 281
Japan 300
Jefferson, R. 144
Jensen, K. 70
job security 269–70
Joerges, C. 4
John Fairfax Publications v Birt 271–2, 276
judicial policy 298–9
Kahin, B. 47–8
Kamm, O. 174
Kapcynski, A. 144
Keen, A. 174
Kew Royal Botanical Gardens 191
Keynes, J.M. 16
Kilian, A. 142
Kipling, R. 202
Klimis, G. 292
Knol 174, 182, 184
knowledge
assets, property and capital in 155–7
politics of 172–98
spillovers 36–7
knowledge production model 222, 224
Kondo, E. 43
Koons, J. 215
Koops Martin v Dean Reeves 273
Kores Manufacturing Co. Ltd v Kolok Manufacturing Co. Ltd 274, 278
Kretschmer, R. 292
Kronz, H. 23
Labich, K. 41
labour, freedom from coercion 269–70, 270, 278–9
labour law 300
and individual creativity 259–62
labour markets, deregulation of 269–70
Lambert Review 230
Lamberton, D. 40
Landes, W. 293
Lanier, J. 174
Lanjouw, J. 45–6
large firms 292
disintegration of the large firm 286
Lastowka, G. 178
Latour, B. 169
Lecocq, X. 133
legal aid 17
legal services 96–7, 296
legislative intervention 299–300
Lemley, M. 57, 73
Lerner, J. 44
Lessig, L. 192–3
Levine, D. 44
liberal capitalism 286
licences of right 83, 84, 92
licensing 40, 71
compulsory 24–5, 82–3, 111
open licensing systems 4–5, 158–63
open source licensing 132–3, 139, 147–9, 194
US universities 232, 233–4
licensor obligations 160, 162
Lindner v Murdoch’s Garage 272
litigation, patent 17, 38, 95–6
costs 45–6
Littlewoods Organisation Ltd v Harris 276
local environment 301, 309–10
London newspapers 200, 201
Los Angeles Times v Free Republic 205–12
Luckmann, T. 156
Luhmann, N. 169
Lumley v Wagner 279–80
Macdonald, S. 29, 41, 42, 61, 65–6
Machlup, F. 29, 31, 38–9, 40, 47
Macquarie University 241
Maggbury v Hafele 269
managers, and researchers 294
Manber, U. 184
Mandeville, T. 38, 40
Mansfield, E. 32, 36, 43
Marginson, S. 228
market 6
market-based exchanges of information 64–8
technology markets 39–40
market harm 211
market positioning 136–7
market power 12
types of 12–13
market pull innovation 222
Martinez, C. 41
Maskus, K. 1
Massachusetts Route 128 293
Mathews, J. 16
Maurer, S. 141, 142, 144
<table>
<thead>
<tr>
<th>Author/Title/Institution/Location</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>May, C.</td>
<td>225, 227</td>
</tr>
<tr>
<td>McDonnell, B.</td>
<td>67</td>
</tr>
<tr>
<td>McRobbie, A.</td>
<td>286</td>
</tr>
<tr>
<td>Melbourne University</td>
<td>240–1</td>
</tr>
<tr>
<td>Merchant of Venice (Shakespeare)</td>
<td>277</td>
</tr>
<tr>
<td>Merck Gene Index</td>
<td>185</td>
</tr>
<tr>
<td>Merges, R.</td>
<td>44, 64–5, 66–7, 69, 290, 291, 292, 293, 295, 296, 298</td>
</tr>
<tr>
<td>Metro-Goldwyn-Mayer Studios Inc. v Grokster Ltd</td>
<td>181</td>
</tr>
<tr>
<td>Meurer, M.</td>
<td>11, 30, 33, 38, 46</td>
</tr>
<tr>
<td>Michaels, T.</td>
<td>140</td>
</tr>
<tr>
<td>Mill, J.S.</td>
<td>204, 214</td>
</tr>
<tr>
<td>Mischlewski, D.</td>
<td>37</td>
</tr>
<tr>
<td>Missouri Botanical Garden</td>
<td>190</td>
</tr>
<tr>
<td>Mithal, V.P.</td>
<td>81, 82, 86–7</td>
</tr>
<tr>
<td>Mobilesoft</td>
<td>278</td>
</tr>
<tr>
<td>mobility 5–6, 254, 257, 259–60, 261, 262</td>
<td></td>
</tr>
<tr>
<td>anti-poaching clauses 272–4, incentives 292–3</td>
<td></td>
</tr>
<tr>
<td>model law of intellectual property 15</td>
<td></td>
</tr>
<tr>
<td>Mohan, R.</td>
<td>90</td>
</tr>
<tr>
<td>Moir, H.</td>
<td>32</td>
</tr>
<tr>
<td>Monash University</td>
<td>241</td>
</tr>
<tr>
<td>money, measurement by 23–5, monopoly power 42</td>
<td></td>
</tr>
<tr>
<td>Monotti, A.L.</td>
<td>228, 230, 238, 239, 240, 242</td>
</tr>
<tr>
<td>Monthly Chronicle</td>
<td>203</td>
</tr>
<tr>
<td>Mooney, B.</td>
<td>45</td>
</tr>
<tr>
<td>Mowery, D.</td>
<td>59, 62</td>
</tr>
<tr>
<td>multiple 24, 25</td>
<td></td>
</tr>
<tr>
<td>Murray, F.</td>
<td>70</td>
</tr>
<tr>
<td>Myers, K.</td>
<td>180, 182</td>
</tr>
<tr>
<td>Myriad Genetics</td>
<td>159</td>
</tr>
<tr>
<td>national innovation surveys 43, 47</td>
<td></td>
</tr>
<tr>
<td>National Institutes of Health (NIH) (USA) effectiveness of diffusion 236</td>
<td></td>
</tr>
<tr>
<td>Grants Policy 232</td>
<td></td>
</tr>
<tr>
<td>principles for patenting 234–5</td>
<td></td>
</tr>
<tr>
<td>National Library of Medicine (USA) 236</td>
<td></td>
</tr>
<tr>
<td>National Museum of Natural History at the Smithsonian Institute 191</td>
<td></td>
</tr>
<tr>
<td>National Principles of Intellectual Property (NP) (Australia) 238</td>
<td></td>
</tr>
<tr>
<td>National Research Development Corporation (NRDC) (UK) 230 National Survey of Research Commercialisation Years 2003 and 2004 (NSRC) (Australia) 225, 227</td>
<td></td>
</tr>
<tr>
<td>negative externalities 30</td>
<td></td>
</tr>
<tr>
<td>Neglected Disease licensing 144–5</td>
<td></td>
</tr>
<tr>
<td>Nelson, R.</td>
<td>39, 69</td>
</tr>
<tr>
<td>Netanel, N.W.</td>
<td>193</td>
</tr>
<tr>
<td>network effects 136</td>
<td></td>
</tr>
<tr>
<td>Network for Open Scientific Innovation (NOSI) 144</td>
<td></td>
</tr>
<tr>
<td>networks 229, 301</td>
<td></td>
</tr>
<tr>
<td>see also clusters</td>
<td></td>
</tr>
<tr>
<td>new street literature 205–12</td>
<td></td>
</tr>
<tr>
<td>New York Botanical Garden 190–1</td>
<td></td>
</tr>
<tr>
<td>newspapers 200–5</td>
<td></td>
</tr>
<tr>
<td>nineteenth century 200–1</td>
<td></td>
</tr>
<tr>
<td>Nibart-Devouard, F.</td>
<td>183</td>
</tr>
<tr>
<td>Nicol, D.</td>
<td>4, 60, 62, 63, 64, 65, 67–8, 72–3</td>
</tr>
<tr>
<td>Nielsen, J.</td>
<td>60, 62, 64, 65, 67–8, 72–3</td>
</tr>
<tr>
<td>non-competition clauses see restrictive covenants</td>
<td></td>
</tr>
<tr>
<td>non-disclosure clauses 294–6, 298</td>
<td></td>
</tr>
<tr>
<td>non-exclusive licences 159–60</td>
<td></td>
</tr>
<tr>
<td>non-proprietary business opportunities 136–7</td>
<td></td>
</tr>
<tr>
<td>non-proprietary tool kit 139</td>
<td></td>
</tr>
<tr>
<td>Nordhaus, W.</td>
<td>11</td>
</tr>
<tr>
<td>Novartis 92–3</td>
<td></td>
</tr>
<tr>
<td>novelty 254</td>
<td></td>
</tr>
<tr>
<td>Nupedia 176</td>
<td></td>
</tr>
<tr>
<td>objectives of research universities 240–1</td>
<td></td>
</tr>
<tr>
<td>Office of Best Practice Regulation 111</td>
<td></td>
</tr>
<tr>
<td>Olson, M.</td>
<td>26</td>
</tr>
<tr>
<td>online media 172–98</td>
<td></td>
</tr>
<tr>
<td>Encyclopedia of Life 172, 174, 184–92</td>
<td></td>
</tr>
<tr>
<td>open access 75–6, 139, 147, 190</td>
<td></td>
</tr>
<tr>
<td>open arenas 158, 167–8</td>
<td></td>
</tr>
<tr>
<td>Open Hardware 132</td>
<td></td>
</tr>
<tr>
<td>open licensing systems 4–5, 158–63</td>
<td></td>
</tr>
<tr>
<td>BiOS 63, 143–4, 161–2</td>
<td></td>
</tr>
<tr>
<td>Cancer Research UK 159–61</td>
<td></td>
</tr>
<tr>
<td>PIPRA 63, 162–3</td>
<td></td>
</tr>
<tr>
<td>open review 19–20</td>
<td></td>
</tr>
<tr>
<td>open science 164</td>
<td></td>
</tr>
</tbody>
</table>
open source biotechnology (OSB) 5, 129–53
anticommons problem 130, 131–2, 138–9
challenges in implementing 146–50
excessive proprietary control problems 131, 138–9
incentives for participation 134–8
key elements of approach 132–4
nature of 129–30
real-world examples 140–6
Open Source Definition (OSD) 148
Open Source Initiative (OSI) 148
open source licensing 132–3, 139, 147–9, 194
open source model 166
open source research platforms 166–7
openness 5, 154–71
intellectual property-based structural arenas for 167–8
possibilities for establishing 158
with as few restrictions as possible 165
within a community 166–7
within the research group 165
within the research project 165–6
Oppenheim, C. 41, 45
Oppenheim, J. 179–80
originality 253–4
orphan drugs 21, 23
orphan works 189, 194
Otis Elevator Co. Pty Ltd v Nolan 280–1
outsourcing to India 90–1
over-regulation 307
P2P Foundation 132
Page, R. 192
patent examiners 3, 81–2, 89, 90, 93–4
patent interpretive community 93–4
Patent Lens 143
patent offices 80–1
India 80–100
patent portfolio races 44–5, 71, 72
patent searches 111
patent secretaries 81
patents 3–4, 11–28, 307
abuse of the patent system 47
agreed patent database 20–2
Australian competition law and 6, 101–25
broadened scope of patentable subject matter 223
commercialisation of university research 228, 234–5
costs and benefits of patent systems 29–54
decline in quality 18–19
default rules in Australia 297
evolution of 13–14
incentives for innovation in firms and 251, 250–7, 262
patents as incentives to invent 251–3
patents regulating competition 256
problems with competition 255–6
India’s strategy on 90–1
and innovation in biomedicine 55–79
strong patent rights and small firms 63–9
strong patent rights and universities 60–3
strong patent rights and weak patent standards 68–74
need for reform 11–17
reform proposals 17–26
penicillin 14
personal conflicts of interest 226
pesticides 84
persuasion market power 12–13
pervasive incentives 253–5
see also incentives
Petrusson, U. 155, 156, 157, 158
pharmaceuticals industry 14, 15, 33
exploitation incentives 292
India 82, 84, 85, 86, 92–3, 97
encouragement of outsourcing R&D to 90–1
patents as incentives to invent 252–3
**Index**

*Physical Review Letters* 179
pipeline protection 85, 87
Pisano, G. 75, 288
plagiarism 180–2
Plant, A. 38
politics of knowledge 172–98
portfolio patent races 44–5, 71, 72
positive externalities 30, 36–7
Posner, R. 293
post-Chandlerian school 64, 76
post-grant opposition 95
Powell, W. 135, 296
Prakash, V.V. 135
pre-assignment clauses 294–6
pre-grant opposition 95
pre-incubators 167–8
Pressman, L. 60
price fixing 121
prior art searches 19–20
prior use defence 111
privity doctrine, ignorance of 269, 270–77
process benefits 135
production incentives 290–1
productivity 44
property, knowledge 155–7
prospect theory 108
provincial newspapers 201
psychological contract 291
public choice theory 46
Public Intellectual Property Resource for Agriculture (PIPRA) 63, 162–3
Public Library of Science 132, 185
public research organizations (PROs) 157–8
Public Resource.org 191
publication 230
PubMed Central 236
pure research see basic research
quality of patents 18–19
Quankiki 185
Queensland University 241
Quiggin, J. 205–6, 210, 211, 212
Qwiki 185
Rai, A. 141, 142
*Railway Times* 203
Ralston, L. 240
Rao, P. Narasimha 85
rational ignorance 73
Raymond, E. 174
*Re Fisher* 72
recombinant DNA technology 57–60, 61
re-contextualisation 211
Red Hat 142
regulation costs 36, 45–7
regulatory capture 46, 308
regulatory competition 299–300
Reichman, J. 4, 15
’relates to’, interpretation of 115–16
renewal fees 111
rent extraction 91
representative democracy 204
reputation 12
Research Councils UK 230
research and development, outsourcing to India 90–1
research directions 38
research groups, openness within 165
research platforms for openness 164–8
research projects, openness within 165–6
researchers, and managers 294
resource allocation 35, 42–5
Responsible Use of Public Research programme 157
restrictions justified on restrictions on competition 109–10
openness with as few as possible 165
restrictive covenants 6, 260, 261–2, 267–84
complaints common to recent decisions 268–79
corruption of common law doctrine 269, 270, 275–7
human rights dimension 269–70, 270, 278–9
ignorance of privity doctrine 269, 270, 277–8
inept adoption of accounting language 268–9, 270, 270–5
practical measures 279–81
split entitlements 294–6, 298
Reuveni, E. 178
reward theory 108
Ricketson, S. 228, 230, 238, 242
rigour 1, 3–4
Riley, J. 273, 278, 298, 300
Rimmer, M. 175
Rio Convention on Biological Diversity 185, 192
Roberts, J. 288
Robin, S. 286
Robinson, J. 206, 208
royalties 25
safe harbours 180–2, 193–4
Sainsbury Review 231
Sali, A. 141
Samuel Report 116, 117
Sand, I.-J. 4
Sanger, L. 173, 174, 176, 183
Sanger Institute 141
Saxenian, A. 292, 293, 299
scale 12
Schankerman, M. 45–6
Scherer, F. 32, 33
Schollin, K. 164
Scotchmer, S. 69
science, public perceptions of 253
Science Commons 132
second enclosure movement 132
secrecy 41–2
see also trade secrets
Sell, S. 15, 16
semiconductor industry 65, 68–9
service provision 136
Shakespeare, W. 277
Shaw, H. 190
Shawn Bentley Orphan Works Act 189
Sheehan, J. 41
Shepard, L. 199, 212, 214
Shiva, V. 145
sideground intellectual property 166–7
Silberston, Z. 32
Silicon Valley 281, 293, 296
simultaneous invention 44
Sjoberg, L. 175
SklogWiki 185
Slow Food project 145
small firms 61–2, 74–6
strong patent rights and 63–9
Smithsonian Institute 191
SNP Consortium 76, 137, 185
social amenity of the locality 301
social capital policy 301
social constructions 156–7, 169
software programs, open source 145–6
solicitation 277
Sparling, D. 75
specific market power 13
‘specific, substantial and credible’ standard 111
Spekkens, R.W. 179
Spender, J.-C. 169
spin-off companies 60–1
split entitlements 6, 285–305
cluster policy and innovation 290–3
complementary policies 300–2
furthering legal policy 293–300
policy context 285–90
policy rationales 290–3
Sprouse, G. 179
St James’ Gazette 202
stable workforce 273–4
Stallberg, C. 295
Stallman, R. 41, 139
standardisation, international 7
Stern, S. 70
Stokes, D. 56
Stone, K. 270, 291
strategic patenting 32
street literature 4, 199–217
new 205–12
old 199–205, 207
strong patent rights 3, 56–7
positives of 63–4
and small firms 63–9
and universities 60–3
and weak patent standards 68–74
and follow-on innovation 69–71
twenty-first century 71–4
structural transformation 155, 168
sub-licensing 162
Sulston, J. 141
Suthersanen, U. 286, 292
Sykes, Sir R. 231
systems 4, 309
tacit knowledge 3, 60–1, 260, 292
Tapscott, D. 173, 184–5
Taylor, C. 32
Taylor, G. 142
technical arbitration 4, 17–18
technology 254
development and OSB 133
markets 39–40
technological hold-ups 39, 69–71
technology push innovation 222, 230
Index

Teubner, G. 4, 183–4
The Synaptic Leap (TSL) 142
third-line forcing 120, 121
Thomson, J. 250
threshold tests 107, 108
Thurbon, J. 16
Times, The 202, 204
Tkacz, N. 174
total factor productivity 44
Towse, R. 286
Trade Related Aspects of Intellectual Property (TRIPs) 7, 16–17, 22, 26, 74, 154, 300
India and 84–6, 94, 97
role of corporations 15–16
transitional provisions 85
trade secrets 260–1, 270–2, 281, 300
trademarks 47
trading of patents 40
Traditional Knowledge Digital Library 95
Traditional Knowledge Resources Classification System 95
training of patent examiners 93–4
transaction costs 117
impacts of patent system 36, 45–7
transactions 1
Transfield Pty Ltd v Arlo International Ltd 114–15
transformation 208, 211
transitional arrangements 119
translational research 55
Treaty on Access to Knowledge (A2K) 194
trilateral 26
trolling 18–19
Tropical Diseases Initiative (TDI) 141–2
United Kingdom (UK) 95, 289
commercialisation of university research 223, 230–1
licences of right 84
Patents and Designs Act 1919 84
United States of America (USA) 300
Bayh–Dole Act 58–9, 225, 232, 233, 234, 243
biotechnology companies 63
commercialisation of university research 231–6, 243
reviews and reform recommendations 232–6
Constitution 13
Digital Millennium Copyright Act 1998 181, 182
fair use doctrine 180–1
history of biomedical research 57–60
induced patents 34, 36
interference procedure 18
Orphan Drug Act 1983 21, 23
Shawn Bentley Orphan Works Act 2008 189
WTO action against India 85, 87
United States Patent and Trademark Office (USPTO)
capacity building in developing countries 93–4
interference procedure 18
universal rules 309–10
universities 167–8
commercialisation of research 5, 221–49
strong patent rights and 60–3
University Companies Association (UNICO) 225, 231
Uruguay Round 43, 84
use of patents 31–6, 43
user benefits 135–6
uses of intellectual property rights 2, 4–5
valley of death 167
Van Caenegem, W. 68, 282, 292, 298
Van Doren, C. 172
Van Pottelsberghe, B. 45
Venter, C. 59
virtual herbarium 190–1
Vitale, M. 75
voluntarism 6
voluntary obligations to disseminate research 236, 239
Wadman, M. 57
Wales, J. 176, 177
Wallis, R. 292
Walsh, J. 39, 70–1
Walter v Howe 202
Walter v Lane 204
Walter v Steinkopff 202
Washington Post 208
Watt, J. 39

Christopher Arup and William van Caenegem - 9781848449039
Downloaded from Elgar Online at 03/06/2019 06:21:35AM via free access
Weisburst, S. 33
Weiss, L. 16
Westenholz, A. 296
wiki communities 177
Wikia Inc. 177
Wikia Search 177
Wikibooks 177
Wikileaks 182
Wikimedia Commons 177
WikiMedia Foundation 177, 181–2, 182–3
Wikinews 177
authorship and ownership 177–80
imitators, rivals and competitors 182–4
plagiarism, fair use and safe harbours 180–2
Wikiquote 177
wikis 172
WikiScanner 182
Wikisource 177
Wikispecies 177

Wilkins v Aikin 202–3, 207–8
Williams, A. 173, 184–5
Williams, R. 200
Wilson, E.O. 185–6, 191, 192
Wingate, P. 205
Winter, A. 179
Wookieepedia 182
Woolworths v Olson 271
work-for-hire doctrine 291–2, 300
World Fairs 38
World Trade Organization (WTO) 84–5
dispute resolution between India and USA 85, 87
India 85, 87, 94
TRIPs see Trade Related Aspects of Intellectual Property
World War I 13
Wright brothers 39
Wright v Gasweld Pty Ltd 271, 276
Yencken, J. 240
Yeo, R. 175
Ziedonis, R. 65, 68–9
Zimmer, C. 184
Zimmerman, D. 5
Zittrain, J. 173–4, 176, 180